Quote:
The touted measure of efficacy on these drugs is relapse reduction . . . that HOPEFULLY leads to slower disease progression for some. Even from the trials, which was a very short-term measure of efficacy, they have not slowed the disease to anywhere near the degree that they apparently reduced relapses. There is a lot more to this disease then transient inflammed lesions and relapses . . . 
|
Truer words were never said! If you look at the many MS drug trials, the companies who conduct them hang their sales and marketing hats on reduced relapses, reduction in number of lesions in the brain and reduced chance of progression. Yet the disease marches on in the vast majority of patients. You would think that if MS was solely an auto-immune disease, these drugs would have a much greater effect on a far greater percentage of the people who used them. But that simply is not the case and recent analysis of these trials is starting to show that the drugs are not doing what the companies have advertised.
Any benefits to MS patients is so hit and miss and like we have read, causes a huge amount of frustration for them. I've watched this for over 40 years and it certainly takes its toll on everyone associated with the disease.
Harry